New cancer clinical trial: Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation

Published on: February 04, 2019 at 10:30PM

• Tweet
• Share
• Share
• Share
• Share